Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: An experience in Taiwan

Gynecologic Oncology

Volumn 94, Issue 2, 2004, Pages 393-397

  Liu, Fu Shing ^a,b   Ho, Esther Shih Chu ^a,b   Hung, Man Jung ^a,b   Hwang, Sheau Feng ^a   Lu, Chien Hsing ^a   Ke, Yu Min ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Carboplatin; Gemcitabine; Ovarian cancer; Paclitaxel; Peritoneal cancer; Relapse

Indexed keywords

ANTIEMETIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; GEMCITABINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG INFUSION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; LIVER TOXICITY; NAUSEA; OVARY CARCINOMA; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; SALVAGE THERAPY;

EID: 3543089799     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.05.017     Document Type: Article

References (20)

1. McGuire W.P., Ozols R.F. Chemotherapy of advanced ovarian cancer. Semin. Oncol. 25:1998;340-348
2. Markman M., Bookman M.A. Second-line treatment of ovarian cancer. Oncologist. 5:2000;26-35
3. van Moorsel C.J.A., Peters G.J., Pinedo H.M. Gemcitabine: future prospects of single-agent and combination studies. Oncologist. 2:1997;127-134
4. Huang P., Chubb S., Hertel L.W., Grindey G.B., Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51:1991;6110-6117
5. Heinemann V., Hertel L.W., Grindey G.B., Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res. 48:1988;4024-4031
6. Ozols R.F. The role of gemcitabine in the treatment of ovarian cancer. Semin. Oncol. 27(Suppl. 2):2000;40-47
7. Peters G.J., Bergman A.M., van Haperen R., Veerman G., Kuiper C.M., Braakhuis B.J.M. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol. 22:1995;72-79
8. Bergman A.M., Ruiz van Haperen V.W.T., Veerman G., Kuiper C.M., Peters G.J. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin. Cancer Res. 2:1996;521-530
9. van Moorsel C.J.A., Pinedo H.M., Veerman G., Bergman A.M., Kuiper C.M., Vermorken J.B., et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br. J. Cancer. 80:1999;981-990
10. Aapro M.S., Martin C., Hatty S. Gemcitabine - A safety review. Anti-Cancer Drugs. 9:1998;191-201
11. Geertsen P., Hansen M., Stroyer I., Hansen S. Combination chemotherapy with platinum, paclitaxel, and gemcitabine in patients with relapsed ovarian carcinoma. Proc. Am. Soc. Clin. Oncol. 18:1999;A1395. (abstract)
12. Hansen S.W., Anderson H., Boman K., Hansen M., Havsteen H., Rosenberg P., et al. Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV. Proc. Am. Soc. Clin. Oncol. 18:1999;A1379. (abstract)
13. Bookman M.A. Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the gynecologic oncology group (GOG-0182). Semin. Oncol. 29(Suppl. 1):2002;20-31
14. Mutch D.G., Grigsby P.W., Markman M., Rubin S.C. Management of late effects of treatment. Hoskins W.J., Perez C.A., Young R.C. Principles and practice of gynecologic oncology. third ed.:2000;669-692 Lippincott Williams and Wilkins, Philadelphia
15. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92:2000;205-216
16. Rustin G.J., Nelstrop A.E., Bentzen S.M., Bond S.J., McClean P. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J. Clin. Oncol. 18:2000;1733-1739
17. Rose P.G., Mossbruger K., Fusco N., Smrekar M., Eaton S., Rodriguez M. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol. Oncol. 88:2003;17-21
18. Nagourney R.A., Brewer C.A., Radecki S., Kidder W.A., Sommers B.L., Evans S.S., et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol. Oncol. 88:2003;35-39
19. D'Agostino G., Amant F., Berteloot P., Scambia G., Vergote I. Phase II study of gemcitabine in recurrent platinum- and paclitaxel-resistant ovarian cancer. Gynecol. Oncol. 88:2003;266-269
20. Hansen S.W. Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma. Semin. Oncol. 29(Suppl. 1):2002;17-19